GW Henssler & Associates’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$448K Buy
4,327
+7
+0.2% +$625 0.02% 149
2026
Q1
$310K Buy
4,320
+333
+8% +$25.7K 0.01% 167
2025
Q4
$316K Sell
3,987
-20
-0.5% -$1.58K 0.02% 161
2025
Q3
$302K Hold
4,007
0.02% 156
2025
Q2
$276K Sell
4,007
-327
-8% -$21.4K 0.01% 148
2025
Q1
$294K Buy
+4,334
New +$259K 0.02% 142
2024
Q3
Sell
-251,510
Closed -$14.9M 200
2024
Q2
$14.9M Buy
251,510
+4,262
+2% +$267K 0.89% 52
2024
Q1
$19.7M Sell
247,248
-21,421
-8% -$1.64M 1.16% 40
2023
Q4
$21.2M Sell
268,669
-8,567
-3% -$610K 1.4% 28
2023
Q3
$19.4M Buy
277,236
+4,342
+2% +$308K 1.32% 31
2023
Q2
$18.9M Buy
272,894
+8,449
+3% +$601K 1.24% 39
2023
Q1
$19.7M Buy
264,445
+3,972
+2% +$333K 1.31% 33
2022
Q4
$24.3M Buy
260,473
+132
+0.1% +$12.7K 1.7% 19
2022
Q3
$24.8M Buy
260,341
+2,052
+0.8% +$203K 1.86% 11
2022
Q2
$23.9M Sell
258,289
-1,955
-0.8% -$191K 1.78% 17
2022
Q1
$26.3M Sell
260,244
-1,952
-0.7% -$205K 1.6% 18
2021
Q4
$27M Sell
262,196
-1,701
-0.6% -$157K 1.73% 13
2021
Q3
$22.4M Sell
263,897
-48,861
-16% -$4.09M 1.55% 17
2021
Q2
$26.1M Sell
312,758
-2,823
-0.9% -$231K 1.72% 13
2021
Q1
$23.7M Sell
315,581
-865
-0.3% -$63K 1.7% 12
2020
Q4
$21.6M Buy
316,446
+964
+0.3% +$62.7K 1.65% 13
2020
Q3
$18.4M Buy
315,482
+1,311
+0.4% +$81.6K 1.56% 22
2020
Q2
$20.4M Sell
314,171
-3,925
-1% -$247K 1.79% 14
2020
Q1
$18.9M Sell
318,096
-7,263
-2% -$485K 1.91% 10
2019
Q4
$24.2M Sell
325,359
-116
-0% -$8.14K 2% 8
2019
Q3
$20.5M Buy
325,475
+21,079
+7% +$1.25M 1.83% 8
2019
Q2
$16.6M Sell
304,396
-3,145
-1% -$169K 1.5% 20
2019
Q1
$16.6M Buy
307,541
+12,941
+4% +$799K 1.52% 19
2018
Q4
$19.3M Sell
294,600
-2,811
-0.9% -$210K 2.06% 8
2018
Q3
$23.4M Buy
297,411
+8,879
+3% +$635K 2.13% 8
2018
Q2
$18.6M Buy
288,532
+108,882
+61% +$7.18M 1.82% 10
2018
Q1
$11.2M Buy
179,650
+7,416
+4% +$532K 1.12% 40
2017
Q4
$12.5M Buy
172,234
+4,454
+3% +$324K 1.17% 38
2017
Q3
$13.6M Buy
167,780
+2,046
+1% +$162K 1.37% 22
2017
Q2
$13.3M Buy
165,734
+6,216
+4% +$491K 1.39% 19
2017
Q1
$12.5M Buy
159,518
+4,903
+3% +$391K 1.35% 25
2016
Q4
$12.2M Sell
154,615
-363
-0.2% -$29.4K 1.35% 24
2016
Q3
$13.8M Sell
154,978
-4,204
-3% -$397K 1.58% 17
2016
Q2
$15.2M Sell
159,182
-2,593
-2% -$258K 1.75% 14
2016
Q1
$16.8M Sell
161,775
-8,171
-5% -$795K 1.97% 10
2015
Q4
$16.6M Sell
169,946
-8,405
-5% -$823K 1.96% 9
2015
Q3
$17.2M Sell
178,351
-1,452
-0.8% -$153K 1.97% 8
2015
Q2
$18.9M Sell
179,803
-9,207
-5% -$941K 2.05% 7
2015
Q1
$19.5M Sell
189,010
-1,777
-0.9% -$180K 2.26% 6
2014
Q4
$18.4M Sell
190,787
-1,931
-1% -$170K 2.06% 7
2014
Q3
$15.3M Sell
192,718
-1,224
-0.6% -$96.5K 1.86% 15
2014
Q2
$14.6M Sell
193,942
-8,114
-4% -$613K 1.77% 14
2014
Q1
$15.1M Sell
202,056
-15,021
-7% -$1.06M 1.78% 14
2013
Q4
$15.5M Buy
217,077
+3,692
+2% +$237K 1.82% 17
2013
Q3
$12.1M Buy
213,385
+3,482
+2% +$207K 1.56% 25
2013
Q2
$12M Buy
+209,903
New +$12.2M 1.65% 25

Other funds holding CVS

GW Henssler & Associates's CVS Position: Q2 2026 in Review

GW Henssler & Associates increased its CVS Health (CVS) stake by 0.16% in Q2 2026, buying an estimated $625 and bringing the position to 4,327 shares worth $448K. The position accounts for 0.02% of the portfolio, ranked #149.

GW Henssler & Associates first reported a position in CVS in Q2 2013 and has held it in 51 quarters since. The position peaked at $27M in Q4 2021. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • GW Henssler & Associates held 4,327 shares of CVS Health worth $448K as of Q2 2026.
  • GW Henssler & Associates bought 7 CVS Health shares in Q2 2026, an estimated $625.
  • CVS Health made up 0.02% of GW Henssler & Associates's portfolio in Q2 2026, its #149 holding.
  • GW Henssler & Associates first reported a position in CVS Health in Q2 2013 and has held it in 51 quarters since.
  • GW Henssler & Associates's CVS Health position peaked at $27M in Q4 2021.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on GW Henssler & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.